Reduction of cardiac TGFβ-mediated profibrotic events by inhibition of Hsp90 with engineered protein
Myocardial fibroblast activation coupled with extracellular matrix production is a pathological signature of myocardial fibrosis and is governed mainly by transforming growth factor TGFβ-Smad2/3 signaling. Targeting the ubiquitous TGFβ leads to cellular homeostasis deregulation with adverse consequences. We previously showed the anti-fibrotic effects upon downregulation of 90-kDa heat shock protein (Hsp90), a chaperone that associates to the TGFβ signaling cascade. In the present study, we use a fluorescent-labeled Hsp90 protein inhibitor (CTPR390–488) with specific Hsp90 binding properties to reduce myocardial pro-fibrotic events in vitro and in vivo. The mechanism of action involves the disruption of TGFβRI-Hsp90 complex, resulting in a decrease in TGFβ signaling and reduction in extracellular matrix collagen. In vivo, decreased myocardial collagen deposition was observed upon CTPR390–488 treatment in a pro-fibrotic mouse model. This is the first study demonstrating the ability of an engineered Hsp90 protein inhibitor to block collagen expression, reduce the motility of myocardial TGFβ-activated fibroblasts and ameliorate angiotensin-II induced cardiac myocardial fibrosis in vivo. ; This work was supported by the Spanish Ministerio de Economia, Industria y Competitividad [BIO2015-72124-EXP] and [BIO2016- 77367-R], and the European Research CouncilERC-2014-CoG-648071-ProNANO. The Instituto de Formación e Investigación Marqués de Valdecilla IDIVAL [InnVal 15/31] and [InnVal 17/22], and the FEDER European Union, SODERCAN "Proyecto Puente 2017".